BOX 1 Conjugate Technology for the Developing World—Issues and Potential Problems: S. Pneumoniae Vaccines

  • Incomplete serotype coverage

  • Variable immunogenicity

  • Possible limited effectiveness

  • Potential for ecologic replacement

  • High manufacturing costs

  • Quality control challenge

  • Difficult technology transfer

  • Complex delivery (multiple doses/injection)

SOURCE: Russell, 1994.

Meningococcal Vaccines14

Currently available vaccines against N. meningitides-caused meningitis are far from optimal, particularly with respect to the population most relevant to the CVI: children. The existing polysaccharide vaccines against serogroups A and C—the most prevalent types in the so-called meningitis belt—provide little or no protection in children under 18 months of age. In addition, the duration of protection of a single dose of Group A vaccine is less than 2 years in children 1 to 4 years of age. For these reasons, A/C polysaccharide vaccines are used in all U.S. military personnel, and many thousands of doses are used for epidemic control. Researchers have developed and are testing in humans a meningococcal A/C conjugate vaccine, which they hope will be immunogenic in infants.

The capsular polysaccharides of the group B meningococcus, which causes disease primarily outside of the meningitis belt, are poorly immunogenic in adults and children. One possible explanation is the group B polysaccharides’ similarity to sialic acid moieties on human tissue. Therefore, vaccine researchers have focused their efforts on alternative cell-surface antigens. These include the


Unless otherwise noted, material in this section is based on presentations by Wendell Zollinger and Carl Frasch.

The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001

Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement